DCGI orders suspension of Serum's India trials of AstraZeneca's COVID-19 vaccine - ANI

India's drug regulator has asked Serum Institute of India to suspend recruitment in its clinical trials of AstraZeneca Plc's potential COVID-19 vaccine in the country until further orders, Reuters partner ANI reported on Friday. V.G. Somani, the drugs controller general of India, has also asked for increased safety monitoring of those already vaccinated with the experimental vaccine, ANI reported, citing an order issued by the regulator. The move places further restrictions on the trials, which have already been put on hold by Serum on Thursday after the DCGI had asked the vaccine maker for details on the suspension of trials overseas, in a show-cause notice that was reviewed by Reuters. Friday's order has been issued after Serum responded to the show-cause notice, according to ANI.